Navigation Links
Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
Date:10/26/2010

SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at Oppenheimer's 21st Annual Healthcare Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, November 2, 2010, at 10:15 a.m. Eastern Time.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Live audio webcast of this presentation will be accessible on the Company's website at www.optimerpharma.com, under the investors section.  Replays of this presentation will be available at the same location for 30 days after the presentation.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates under development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). We recently initiated a rolling submission of our NDA filing to the FDA, and filed a MAA to the EMA (Europe) for fidaxomicin.  Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. We plan to have an NDA submitted to the FDA in the first quarter of 2011.
Additional information can be found at http://www.optimerpharma.com.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer &
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
2. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
3. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
4. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
5. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
8. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
9. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
10. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
11. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... DIEGO , July 29, 2014   Sequenom, ... sciences company that provides innovative genetic analysis solutions, and ... of esoteric laboratory services in the United ... noninvasive prenatal testing patents and applications. "We ... innovation, and patient care, and we welcome the opportunity ...
(Date:7/29/2014)... foam of atom-thick sheets can be made to any ... Rice University. , In microscopic images, the foam ... and walls that reinforce each other. The structure consists ... of graphene oxide that self-assemble with the assistance of ... the foam could find use in structural components, as ...
(Date:7/29/2014)... July 29, 2014  Pomerantz LLP is investigating claims ... or the "Company") (NASDAQ: IPXL).  Such investors are advised ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The ... and/or directors have violated Sections 10(b) and 20(a) of ... On July 29, 2014, Impax Laboratories, Inc. (the "Company") ...
(Date:7/29/2014)... WARRINGTON, Pa. , July 29, 2014 /PRNewswire/ ... company dedicated to advancing a new standard of ... financial results on August 5, 2014 before the ... The Company will host a live teleconference ... day. During the conference call, Discovery Labs, management ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4Tough foam from tiny sheets 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2
... Aug. 7 Medicsight PLC, a subsidiary,of MGT ... an industry leader in the,development of Computer-Aided Detection ... has received approval from the Brazilian regulatory,agency, Agencia ... David Sumner, Chief Executive of Medicsight, commented: ...
... Health Sciences and Photonics, today announced that its analytical solutions ... Safety Monitoring (BFSM) in a mobile laboratory supporting the Beijing ... volatile organic compounds in beverages and pesticides in food products. ... ...
... FORT WAYNE, Ind., Aug. 7 The Alliance ... its 3rd annual international,conference will be held September ... (IPFW) campus., For online registration and more ... "This year,s conference theme is ,Music and Medicine: ...
Cached Biology Technology:Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software 2Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software 3 PerkinElmer Expertise and Solutions Integral to Food Safety Monitoring for the Beijing Games : Methods, Applications Expertise and Instrumentation Deployed in Mobile Laboratory 2 PerkinElmer Expertise and Solutions Integral to Food Safety Monitoring for the Beijing Games : Methods, Applications Expertise and Instrumentation Deployed in Mobile Laboratory 3The Science of Music Meets the Art of Medicine - ARIMM 3rd Annual Conference at IPFW, September 12-13, 2008 2
(Date:7/30/2014)... the first high-resolution map of the carbon stocks ... Per. The new and improved methodology used to ... future market-based carbon economies. The new carbon ... and it provides the critical input to studies ... use, and enforcement purposes. The technique includes the ...
(Date:7/30/2014)... in the journal Scientific Reports , published by ... Ganguly found that while global temperature is indeed increasing, ... instance, while each year,s average hottest and coldest temperatures ... fall within a wider range of potential high and ... means that even as overall temperatures rise, we may ...
(Date:7/29/2014)... by academics in the University of Bristol,s Nutrition and ... liquid calories into account when planning meals. , The ... Study of Ingestive Behavior Conference (SSIB 2014) in Seattle, ... that we do. , The team was led by ... of Experimental Psychology. , As part of a Biotechnology ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3Big data confirms climate extremes are here to stay 2
... awarded to enhance the development of biopharmaceuticals. , In ... important results, such as industrial-scale production of antibodies, stem ... and commercial scale stem cell therapy. , The ... 2 of the Bioprocessing Research Industry Club (BRIC), a ...
... where a pathogen is transmitted between two individuals in ... a disease will spread. New research has laid ... spreading models, which could allow for more targeted prevention ... study, published in Physical Review Letters , outlines ...
... Calif. , Feb. 5, 2013 DigitalPersona, Inc., ... announced that the DigitalPersona ® Eikon ® Touch ... ® 4500 Reader UID edition USB based single ... and Quality Certification (STQC) Directorate, an office of the ...
Cached Biology News:£6.5M in funding to help manufacture the drugs of the future 2£6.5M in funding to help manufacture the drugs of the future 3£6.5M in funding to help manufacture the drugs of the future 4£6.5M in funding to help manufacture the drugs of the future 5Can you predict how a disease will spread in a population? 2DigitalPersona Fingerprint Readers Receive STQC Certification for UIDAI Program in India 2DigitalPersona Fingerprint Readers Receive STQC Certification for UIDAI Program in India 3
Request Info...
... EC135-90 is a compact, highly versatile power supply. ... 500 milliamps, this power supply is ideal for ... well as all types of small format transfer ... voltage or constant current with a continuously variable ...
... The BV-10 offers precision beveling ... and 50m. The unique abrasive ... free for greater control of ... be accomplished very rapidly and ...
Human interferon-beta (IFN-beta). Recognizes amino acids 30-47 of IFN-beta. No cross-reactivity with Human IFN-alpha or IFN-gamma....
Biology Products: